AUTL
Autolus Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$1.38
−2.47%Year over year
Reported trailing growth
- Revenue
- +292.0%
- EBITDA
- +7.3%
- EBIT
- +43.4%
- EPS
- -24.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +44.6%
- EBITDA
- +56.9%
- EPS
- +37.6%
Three-year CAGR
- Revenue
- +130.2%
- EBITDA
- -7.4%
- EBIT
- -16.6%
- Net income
- -30.6%
- EPS
- -24.1%
- Free cash flow
- -28.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026